MBS-COV

DRUG2 trials

Sponsors

Oneness Biotech Co., Ltd.

Conditions

Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)Mild to Moderate COVID-19

Phase 1

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

CompletedNCT05677893

Oneness Biotech Co., Ltd.Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)

Start: 2022-11-07End: 2023-03-30Updated: 2025-03-30

Phase 2

A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients

CompletedNCT05941793

Oneness Biotech Co., Ltd.Mild to Moderate COVID-19

Start: 2023-09-11End: 2024-08-12Updated: 2024-09-19

Related Papers

Safety and antiviral activity of inhaled siRNA SNS812 for treatment of mild-to-moderate COVID-19: a phase 2 randomized trial

Journal of Biomedical Science2026-08-14

Pharmacokinetics and Safety Profile of <scp>SNS812</scp>, a First in Human Fully Modified <scp>siRNA</scp> Targeting Wide‐Spectrum <scp>SARS</scp>‐<scp>CoV</scp>‐2, in Healthy Subjects

Clinical and Translational Science2025-03-014 citations